Natriuretic peptides as emerging biomarkers for coronary artery disease risk assessment

The identification of novel biomarkers for coronary artery disease (CAD) risk stratification remains a critical priority in cardiovascular medicine. While natriuretic peptides – specifically atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) – have long been established as diagnostic and prognostic markers in heart failure, emerging evidence suggests their potential utility extends to CAD risk assessment. Natriuretic peptides are secreted by cardiac myocytes in response to ventricular wall stress and volume overload. ANP, primarily released from atrial tissue, and BNP, predominantly from ventricular myocardium, exert natriuretic, diuretic, and vasodilatory effects while antagonizing the renin-angiotensin-aldosterone system. Recent studies have demonstrated that elevated levels of these peptides are independently associated with increased cardiovascular mortality and incident CAD events, even in patients without overt heart failure. The mechanistic link between natriuretic peptides and CAD is multifaceted. Myocardial ischemia induces left ventricular dysfunction and wall stress, triggering neurohormonal activation and natriuretic peptide release even before clinical symptoms manifest. Furthermore, chronic elevation of these biomarkers may reflect subclinical atherosclerotic burden and endothelial dysfunction. Data from the Framingham Heart Study revealed that BNP levels correlate with CAD risk independent of traditional risk factors, suggesting its potential as an additive risk marker. The clinical implications are substantial. Incorporating ANP and BNP into existing risk assessment algorithms could enhance the identification of high-risk individuals who may benefit from aggressive preventive strategies. The cost-effectiveness and widespread availability of these assays make them attractive candidates for routine screening. However, standardization of measurement techniques and establishment of population-specific reference ranges remain essential prerequisites for clinical implementation. As we advance toward precision cardiovascular medicine, natriuretic peptides represent promising tools for CAD risk stratification. Future research should focus on prospective validation studies, optimal threshold determination, and integration of these biomarkers into comprehensive risk prediction models. The journey from biomarker discovery to clinical utility requires rigorous investigation, but the potential to improve cardiovascular outcomes makes this pursuit worthwhile.